Colchicine for treating SARS-CoV-2 infection in maintenance hemodialysis patients: a prospective, open label, randomized controlled trial - NI

CMC Fluid research Funding0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•Patients with end stage kidney disease who are on maintenance hemodialysis in our institute, who develop SARS-CoV-2 infection and who do not meet exclusion criteria, after written informed consent.

•1.Age < 18 years
•2.Not willing to enter the study
•3.Known hypersensitivity to colchicine.
•4.Inflammatory bowel disease, chronic diarrhea or malabsorption
•5.Previous neuromuscular disease
•6.Cirrhosis, active chronic hepatitis or severe hepatic disease defined by SGOT or SGPT levels three times above the normal upper limit
•7.Treatment with immunosuppressive agents, corticosteroids or interleukine-1 antagonists for 6 months before inclusion
•8.Pregnant or breastfeeding females
•9.Patient currently taking colchicine for indications other than SARS-CoV-2 infection prophylaxis
•10.History of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)
•11.Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study

发起方

CMC Fluid research Funding